Drug Discovery Innovation Programme

LIDE is an award winning oncology contract research organization with 14 years of delivering preclinical drug evaluation services to over 200+ clients worldwide. LIDE offers traditional CRO services for drug evaluation studies like organoids, CDX and PDX models. It has a collection of more than 2300 patient derived xenograft models covering 50+ cancer types, of which 200+ are drug resistant and/or harbor interesting genetic alterations. LIDE's proprietary MiniPDX and IO-FIVE tools offer an evolved approach to drug R&D that maximizes budget efficiency and minimizes time to validation. The company owns AAALAC accredited SPF level Animal Centers, safety level 2 laboratories and world-class, state of the art equipment.

nuantic is a Swiss biotech company using AI to accelerate therapeutic protein and peptide engineering. Its technology efficiently explores the protein sequence space to identify optimized candidates with improved properties, reaching optimization goals such as improved affinity, developability or function often in a single round with 30-90 variants.

Scantox is an integrated preclinical CRO supporting sponsors from discovery through IND-enabling nonclinical development, with operations in Denmark, Sweden, Austria, and the United Kingdom. We combine Discovery, Regulatory Toxicology, and Pharmaceutical Development & Analytical in one coordinated platform - helping clients generate high-quality, regulator-ready data while keeping timelines and execution aligned across disciplines. Scantox is recognized for deep expertise in CNS pharmacology and Göttingen minipig research, with advanced genetic toxicology capabilities including Big Blue® transgenic rodent assays. Founded in 1977, Scantox is today owned by Impilo, the leading Nordic healthcare investment company.

Genedata’s mission is to empower biopharma worldwide to innovate boldly, operate efficiently, and accelerate discovery, development, and manufacturing of next-generation medicines.

Genedata transforms biopharma data into intelligence. Our innovative software solutions combine deep science, technology, and AI domain knowledge. Leading biopharma organizations and cutting-edge biotechs partner with Genedata to digitalize and automate complex data workflows. Our advanced analytics and embedded AI enable data-driven decisions. From early discovery through development to the clinic, Genedata solutions drive innovation and maximize ROI being trusted by customers worldwide for more than 25 years.

CARBOGEN AMCIS leverages its world-class chemistry skills to provide seamless drug substance, drug products development and commercialization services for leading pharmaceutical and biopharmaceutical companies. We help customers create a better world by becoming the partner of choice thanks to our innovative solutions. We offer an array of integrated and customized services operating in a fully cGMP-compliant infrastructure, including dedicated Highly Potent API facilities and a clean room for Antibody Drug Conjugates. Beyond our services, we also provide high-quality Cholesterol and Vitamin D analogs. CARBOGEN AMCIS is owned by Dishman Carbogen Amcis Limited, (India). Learn more about us.

intoDNA is a global precision medicine company that provides biopharma and clinicians with decision-grade insights into DNA damage and repair biology to reduce risk, accelerate timelines, and enable truly precise patient care. Our patented STRIDE® platform delivers single-cell resolution combined with advanced AI-driven data analysis, producing unique, objective, high-sensitivity results validated across therapeutic areas. We know existing modalities can fall short, and we envision a future where the right therapies reach the right patients, at the right time.

The STRIDE technology detects and quantifies DNA damage and repair in situ, down to the individual lesion, powering biomarker discovery, target validation, pharmacodynamic studies, and response prediction across DNA Damage Response, radiotherapeutics, immuno-oncology, and antibody-drug conjugate development. Trusted by leading academic centers and biopharma innovators worldwide, intoDNA delivers this data from early discovery through Phase III, helping teams move faster toward safer, more effective therapies for the patients who need them.

Isogenica is a Cambridge-based biotechnology CRO specialising in VHH single-domain antibody discovery for next-generation biologics. We help biotech and biopharma R&D teams tackle the targets that stall conventional discovery – targets and projects that require specialised antigen and discovery techniques like multipass transmembrane targets and intracellular targets. Backed by the most diverse synthetic VHH libraries available, we work to cut typical discovery timelines in half by accelerating lead selection and reducing downstream engineering rework, giving discovery teams faster access to developable binders for therapeutics, bi-specifics, ADCs, T-cell engagers and other advanced formats.

With 25+ years of discovery experience, well over 100+ programmes delivered and multiple candidates progressed into clinical trials, we work as a genuine extension of partner teams from early discovery through lead selection and engineering. For teams building novel modality or translational programmes around difficult biology, we help reduce early-stage risk and reach key development milestones with fewer surprises downstream.

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.

InSilicoMinds is an AI-driven computational modeling and simulation company accelerating pharmaceutical research and development through advanced in silico technologies. We partner with biotechnology, pharmaceutical, and life sciences organizations to improve decision-making across drug discovery, preclinical research, clinical development, and regulatory submissions. Our expertise spans molecular modeling, molecular dynamics, PBPK modeling, population PK (PopPK), quantitative systems pharmacology (QSP), AI-driven drug discovery, virtual bioequivalence, and regulatory modeling. We combine scientific expertise with artificial intelligence to identify promising drug candidates, optimize formulations, predict clinical outcomes, and reduce development timelines and costs. In addition, we develop intelligent AI copilots and knowledge platforms that automate scientific workflows, streamline data assembly, and enhance productivity for modeling and regulatory teams. By integrating computational science, machine learning, and deep pharmaceutical expertise, InSilicoMinds enables faster, data-driven R&D decisions, helping clients accelerate innovation while improving confidence, efficiency, and the probability of technical and regulatory success.

At Healthcare Business Outlook Magazine, our mission is simple yet profound: to empower healthcare professionals with the knowledge, insights, and best practices they need to succeed in today’s rapidly changing landscape. We understand that a healthcare facility is not just about providing exceptional patient care—it’s also about navigating complex regulatory environments, optimizing financial performance, and leveraging technology to drive efficiency and innovation.

Pharma Business Outlook is more than just a publication, it is a bridge that connects pharmaceutical companies, healthcare providers, and key decision-makers. By fostering discussions on regulatory compliance, emerging market opportunities, and digital transformation, the magazine plays a crucial role in shaping the future of the pharmaceutical ecosystem. Whether exploring the latest innovations in clinical trials or uncovering strategies to enhance patient outcomes, Pharma Business Outlook remains a trusted resource for professionals committed to advancing the industry.

Medhealth Outlook serves as the backdoor to the latest technologies and trends in the healthcare, pharma, and medical industries. The publication follows an inside/outside approach that allows viewers to witness varied and balanced perspectives.

Medical Business Outlook Magazine is a platform dedicated to exploring the growing medical business arena and the solutions that drive it forward. With a sharp focus on medical business operations, strategies, and innovations, the magazine serves as a trusted resource for executives, medical decision-makers, and medical professionals seeking to stay informed and ahead of the curve.

Life Sciences Business Outlook is a premier platform dedicated to showcasing the innovations, advancements, and transformative solutions shaping the life sciences industry. Our magazine serves as a beacon for businesses and professionals seeking cutting-edge insights and actionable strategies to stay ahead in this dynamic sector.

Healthcare Tech Outlook, a print platform offering healthcare decision-makers critical information on adopting, innovating, and building new programs and approaches to enhance their capability to provide care. Healthcare Tech Outlook has been a pioneer in offering a learn-from-peer approach to the healthcare arena, offering technical advice to enhance both the overall healthcare landscape and assist individual care providers from general practitioners and specialists to post-acute care organizations.

Gubra is a disease-agnostic company specializing in peptide-based drug discovery and preclinical contract research services. Operating through three synergistic business units, Biotech, CRO, and Ventures, we combine scientific excellence with strong value creation and a firm commitment to society. Our team of approximately 300 employees collaborates with industry and academia to improve the quality of people’s lives.

Since 2002, Affygility Solutions has provided occupational toxicology, industrial hygiene, and occupational health and safety services to the biotechnology, pharmaceutical, and medical device industries. Trusted by more than 800 clients across 75+ countries, Affygility helps organizations simplify complex compliance processes, protect worker safety, and accelerate product development timelines. Its services include Occupational Exposure Limits (OELs), Acceptable Daily Exposure (ADE) values, Occupational Health Categorization (OHC) reports, Safety Data Sheets (SDSs), and custom toxicology monographs for proprietary compounds. Through its OEL Fastrac+ platform, Affygility delivers fast, accurate toxicology data to support cleaning validation, manufacturing, and regulatory compliance decisions. With an international team based in the United States, Canada, Brazil, Singapore, and the United Arab Emirates, Affygility combines deep scientific expertise with innovative technology to support life sciences organizations worldwide.

Maxwell Biosciences has developed technology that can mimic 10,000+ peptides that naturally exist in the human body, a biomimetic immune system. Our vision is to create health for the world, safely and affordably. Our peptide mimics (Claromers®) have the ability to destroy pathogenic viruses, fungi, bacteria and biofilms without harming healthy cells. Claromers are shelf-stable, microbiome-resilient and low cost. Originally developed for critical infectious diseases, Maxwell’s technology is now entering non-pharmaceutical commercial deployment across cosmetics, personal care, medical coatings and biodefense—with pilot access for select partners. Backed by a decade of research, a robust patent portfolio and leadership with deep expertise in science, military, AI and global health, Maxwell has active collaborative agreements with the US military and governments worldwide. FDA clinical trials are planned for 2026. Maxwell’s AI-first platform enables rapid innovation against the rising threat of resistant pathogens, offering scalable solutions for a healthier planet.

CN1699 is a global medical media platform connecting academia, healthcare institutions, and industry professionals through multilingual news, academic content, and digital outreach. With active networks in Asia, Central Asia & the Caucasus, the Middle East, Europe, and Africa, it supports over 500,000 healthcare users. Key services include the MDLA Digital Library, offering academic resources to universities and libraries, and WeMed, a collaboration program linking medical schools, events, and experts worldwide. As an official media partner for international healthcare exhibitions, CN1699 provides bilingual promotional support through its websites, newsletters, and social media, helping events and organizations achieve targeted visibility and academic impact across global medical markets.

Biocytogen is a global biotech company that drives the discovery of fully human monoclonal, bispecific, multispecific, ADC, VHH, and TCR-mimic antibodies across 1,000+ druggable targets, providing 1M+ authentic antibody sequences through its RenBiologicsTM sub-brand for partnerships. Biocytogen is advancing antibody drug development through innovative technologies. Leveraging gene-editing expertise, it pioneered drug target knock-in humanized models and offers 4,000+ models via BioMiceTM, along with in vivo, ex vivo, and in vitro pharmacology and custom gene-editing services.

Sai Life Sciences is an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO) that works with over 300 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes. Over the past 26 years, Sai Life Sciences has served a diverse set of programmes, consistently delivering value based on its quality and responsiveness. The company has over 3,400 employees across its facilities in India, UK, USA and Japan.

IRBM is a scientific contract research organization (CRO) that stands at the forefront of drug discovery, leveraging a single, unified research facility to accelerate team-based breakthroughs and improve efficiencies from concept to candidate. With a history of contributing to several approved drugs, and its own internal pipeline of oncology and other therapeutic assets, IRBM is powered by deep collaborations and decades of expertise from leading global institutions. Their comprehensive in-house capabilities assist partners in achieving key milestones and progressing towards clinical readiness, positioning IRBM as a major player in driving innovation in the pharmaceutical and biotech fields.